Why the study?
Does the combination of aspirin and a thromboxane synthase inhibitor improve the inhibition of thromboxane synthesis in vivo compared to either drug alone in healthy volunteers?
Population
18 healthy volunteers (12 in the main study, 6 in the low-dose aspirin study)
Design
Cohort
Authors
Loading...
Should not alter antiplatelet regimens; hypothesis-generating for additive in vivo effects in patients.
Does the combination of aspirin and a thromboxane synthase inhibitor improve the inhibition of thromboxane synthesis in vivo compared to either drug alone in healthy volunteers?
Pharmacologic inhibition of serum TxB2 must be virtually complete before thromboxane-dependent platelet activation is significantly influenced in vivo.
Reilly et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: